Track ABCL and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$1.78B
Enterprise Value$1.23B
Revenue (TTM)$75.13M
Net Income (TTM)-$146.41M
Free Cash Flow (TTM)-$174.07M
Financial Health
Cash$560.33M
Net Debt-$552.31M
Debt Ratio0.01
Debt to Equity0.01
Interest Coverage-1.77
Valuation (TTM)
Price to Sales23.74
Price to Earnings-12.18
EV to EBITDA-7.02
Price to Book1.56
Price to Free Cash Flow-10.24
Margins (TTM)
Gross Profit Margin100.00%
EBITDA Margin-233.30%
Operating Income Margin-288.98%
Net Income Margin-194.88%
Free Cash Flow Margin-231.69%
Returns (5Y Avg)
Return on Invested Capital-10.75%
Return on Assets-9.13%
Return on Equity-5.66%
Return on Total Capital-10.75%
Return on Capital Employed-8.75%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue-20.27%
Diluted EPS-11.20%
Total Debt13.68%
Capital Expenditures23.86%
Free Cash Flow-41.92%
CAGR (3Y)
Revenue-46.31%
Diluted EPS-20.05%
Total Debt1.37%
Capital Expenditures-16.19%
Free Cash Flow-67.96%
CAGR (1Y)
Revenue160.56%
Diluted EPS6.26%
Total Debt25.84%
Capital Expenditures-45.44%
Free Cash Flow1000.00%
$5.97+$0.17|+2.93%
52W High$8.44
52W Low$2.75
50D SMA$5.93
200D SMA$4.50
Volume5.07M
Abcellera Biologics Inc
150 W 4th Avenue, Vancouver, BC, Canada, V5Y 1G6
IPO
2020
Employees
562
Industry
Biotechnology
Sector
Healthcare
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20230+2
2
Analyst Ratings
3 analysts covering
Buy67%recommend buy
Buy
2
Hold
1
Sell
0